BHVN Stock Up as Rare Neurological Disease Study Meets Primary Goal [Yahoo! Finance]
Biohaven Ltd. Common Shares (BHVN)
Last biohaven ltd. common shares earnings: 2/25 04:45 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.biohavenpharma.com
Company Research
Source: Yahoo! Finance
BHVN were up 13.7% on Sept. 23 after the company announced positive top-line data from the pivotal BHV4157-206-RWE study, which evaluated its pipeline candidate, troriluzole, for the treatment of spinocerebellar ataxia (SCA), a rare and debilitating neurodegenerative disease. Currently, there are no FDA-approved therapy for the given indication. The study showed the efficacy of troriluzole on the mean change from baseline in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) following three years of treatment. Year to date, shares of Biohaven have gained 7.4% with no change for the industry. Image Source: Zacks Investment Research BHVN's Pivotal BHV4157-206-RWE Study Data The study met the primary endpoint on the change from baseline in the f-SARA at three years in all study population genotypes following treatment with troriluzole (200 mg) in SCA patients. Also, treatment with troriluzole led to statistically significant improvements in the f
Show less
Read more
Impact Snapshot
Event Time:
BHVN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BHVN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BHVN alerts
High impacting Biohaven Ltd. Common Shares news events
Weekly update
A roundup of the hottest topics
BHVN
News
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Bank of America Co. from $52.00 to $62.00. They now have a "buy" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Sanford C. Bernstein from $55.00 to $66.00. They now have an "outperform" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its price target raised by analysts at Royal Bank of Canada from $59.00 to $68.00. They now have an "outperform" rating on the stock.MarketBeat
- Biohaven Ltd. (NYSE: BHVN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $59.00 price target on the stock.MarketBeat
BHVN
Earnings
- 8/8/24 - Miss
BHVN
Sec Filings
- 9/25/24 - Form 4
- 9/23/24 - Form 8-K
- 8/16/24 - Form 8-K
- BHVN's page on the SEC website